Results 1 to 10 of about 9,672 (236)
Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study [PDF]
Clinical and Molecular Hepatology, 2021 Background/Aims Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients. Methods Between 2015 to 2019,
Oidov Baatarkhuu +17 more
doaj +3 more sources
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study [PDF]
The Korean Journal of Internal Medicine, 2022 Background/Aims To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting.
Soon Kyu Lee +21 more
doaj +3 more sources
Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country? [PDF]
International Journal of Infectious Diseases, 2021 Objectives: The aim of this study was to evaluate the efficacy and safety of sofosbuvir/ledipasvir ± ribavirin in Malagasy patients with hepatitis C virus genotypes 1 and 2, in real conditions.
Chantelli Iamblaudiot Razafindrazoto +6 more
doaj +2 more sources
Identification of novel compounds against Trypanosoma cruzi using AlphaFold structures [PDF]
Computational and Structural Biotechnology JournalChagas disease is a neglected tropical zoonosis caused by the protozoan Trypanosoma cruzi. The two approved medications for treating this disease show variable efficacy in the chronic phase, highlighting the need for new therapeutic interventions.
Albert Ros-Lucas +6 more
doaj +2 more sources
Hospital Pharmacy, 2015 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Dennis J, Cada +2 more
openaire +2 more sources
Case Reports in Dermatology, 2021 Tattoos have become increasingly popular worldwide making adverse effects from tattoos a growing concern. In our report, we present a 51-year-old man who developed an unusual allergic reaction to the red ink portions of his tattoos that coincided with ...
Meghan L. McPhie +4 more
doaj +1 more source
The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
One Health & Risk Management, 2020 Introduction. Viral hepatitis C (HCV) is a significant global health problem. The risk of developing chronic HCV is up to 80% of patients, of whom 10-20% can develop liver cirrhosis or hepatocellular carcinoma which can lead to death.
Irina RUSU +2 more
doaj +3 more sources
The Lancet Microbe, 2020 Summary: Background: Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy.
Catherine A Chappell, MD +10 more
doaj +1 more source
Vaccines, 2023 The limited availability of effective treatment against SARS-CoV-2 infection is a major challenge in managing COVID-19. This scenario has augmented the need for repurposing anti-virals for COVID-19 mitigation.
Sneha Bansode +10 more
doaj +1 more source
Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.
PLoS ONE, 2015 Ledipasvir, a direct acting antiviral agent (DAA) targeting the Hepatitis C Virus NS5A protein, exhibits picomolar activity in replicon cells. While its mechanism of action is unclear, mutations that confer resistance to ledipasvir in HCV replicon cells ...
Hyock Joo Kwon +10 more
doaj +1 more source